Fowler et al. demonstrated direct evidence that reduced adiponectin levels correlated with MM progression through in vivo studies, as tumor burden and osteolytic bone disease increased in adipose-deficient mice with myeloma [37]. This evidence concerns the gene ADIPOQ and plasma cell myeloma.